For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Arm 1 Rifaximin SSD | Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD Rifaximin SSD: Study Drug dosing will be 80 mg SSD once daily | 0 | None | 0 | 6 | 0 | 6 | View |
| Arm 2 Placebo | Placebo Placebo: 80 mg placebo once daily | 0 | None | 0 | 6 | 0 | 6 | View |